{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial of Cardiovascular Regenerative Medicine"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either CaVaReM interventions, including stem cells and tissue engineering, or standard care as a control."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were recruited based on eligibility criteria, including diagnosis of heart failure. The study was conducted in a clinical setting."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either CaVaReM interventions, including stem cells and tissue engineering, or standard care as a control."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial was conducted to evaluate the efficacy of cardiovascular regenerative medicine (CaVaReM) in repairing damaged heart tissue."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was improvement in cardiac function over 12 months, with a mean difference of 5.2% (95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, with 100 in the intervention group and 100 in the control group, recruited between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The primary outcome was improvement in cardiac function over 12 months, with a mean difference of 5.2% (95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the intervention group and 1% of the control group, with mild gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by [Funding Source]."
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}